International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group最新文献

{"title":"Clinical observation and immune effect of high-intensity focused ultrasound (HIFU) treatment on patients with colorectal cancer liver metastasis.","authors":"Shasha Wang, Zhanmeng Zhang, Libin Sun, Jiashuo Li, Haowen Liu, Xiaojuan Huang, Jinfeng Cui, Chuyang Zhu, Shibo Wang, Wenzhi Chen, Wensheng Qiu","doi":"10.1080/02656736.2025.2519344","DOIUrl":"10.1080/02656736.2025.2519344","url":null,"abstract":"<p><strong>Background: </strong>This study evaluates the clinical and immune effects of high-intensity focused ultrasound (HIFU) on liver metastases from colorectal cancer (CRC).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 64 CRC patients with liver metastases treated with HIFU at Qingdao University's HIFU Cancer Center. Variables such as sex, age, ECOG status, tumor location, KRAS mutation status, HBV infection, number and size of liver metastases, and previous systemic treatments were analyzed. The impact of systemic treatment lines on progression-free survival (PFS) and overall survival (OS) was assessed. A subgroup of 24 patients receiving HIFU combined with first-line therapy was matched with 21 patients receiving chemotherapy alone for comparison.</p><p><strong>Results: </strong>Sixty-four patients underwent 69 HIFU treatments. Median survival was 52 months, with 1-year survival at 100%, 2-year survival at 93.3% and 3-year survival at 72%. The number of metastases treated with HIFU and systemic treatment lines significantly influenced survival (<i>p</i> < 0.05). Post-treatment serum IL-6 levels decreased significantly (<i>p</i> < 0.001). OS was significantly better in the HIFU + chemotherapy group compared to chemotherapy-only (<i>p</i> < 0.0001).</p><p><strong>Conclusion: </strong>HIFU significantly improves OS in CRC liver metastasis patients and reduces serum IL-6 levels, suggesting enhanced immune responses.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2519344"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platform-based BST-2-targeted microbubbles enhance HIFU therapy and effectively inhibit prostate cancer residual growth.","authors":"Hang Zhou, Jia Tang, Yujie Wan, Jiaqi Gong, Qizhi Wang, Kaifeng Huang, Ruixia Hong, Xinzhi Xu, Fang Li","doi":"10.1080/02656736.2025.2511035","DOIUrl":"10.1080/02656736.2025.2511035","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate the potential of BST2-targeted microbubble-facilitated HIFU therapy for prostate cancer (PCa), and to elucidate the mechanisms of synergistic tumor suppression in residual lesions.</p><p><strong>Methods: </strong>The specificity of BST-2 expression in PCa tumor endothelial cells was established using a cellular co-culture method. The targeting efficacy of Anti-BST-2 antibody-conjugated microbubbles (BST-2-MB) was evaluated both <i>in vitro</i> and <i>in vivo</i>. The therapeutic outcomes of BST-2-MB-augmented HIFU (High-Intensity Focused Ultrasound) for PCa in Balb/c mice were compared with those of non-targeted microbubbles and HIFU alone. Changes in the immunological microenvironment and modulation of BST-2-related oncogenic pathways in residual tumors were analyzed using Western Blot, immunofluorescence, flow cytometry, and ELISA.</p><p><strong>Results: </strong>BST-2 is highly expressed in PCa vascular endothelial cells, and BST-2-MBs show strong targeting efficacy. HIFU combined with BST-2-MB achieved larger ablation volumes and potent inhibition of residual tumor growth. This treatment induced more immunogenic cell death (ICD), DC maturation, and CD8+ T cell infiltration, and significantly downregulated the expression of BST-2, EGFR, pSTAT3, and pErk1/2 compared to other treatments.</p><p><strong>Conclusion: </strong>BST-2-MB combined with HIFU therapy demonstrates a superior synergistic antitumor effect in PCa, effectively inhibiting residual tumors, which offers a novel strategy to enhance HIFU efficacy.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2511035"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thermal ablation included in multimodality treatment predicts enhanced survival in advanced non-small cell lung cancer: a propensity score-matched outcome study.","authors":"Stella Chin-Shaw Tsai, Yi-Min Chen, Yueh-Han Ku, Chia-Hsuan Hsu, Tzu-Hsuan Hsiao, Pin-Hsu Liao, Tzu-Chin Wu, Frank Cheau-Feng Lin","doi":"10.1080/02656736.2024.2449473","DOIUrl":"https://doi.org/10.1080/02656736.2024.2449473","url":null,"abstract":"<p><strong>Background: </strong>Advanced non-small cell lung cancer (NSCLC) presents significant treatment challenges, with limited effective therapies for late-stage patients. This study aimed to evaluate the impact of adding thermal ablation (TA) in treatment regimens for advanced NSCLC to improve survival outcomes.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted at a medical center in Taiwan, analyzing data from 1,083 patients diagnosed with stage IIIB or IV NSCLC between 2008 and 2020. Survival outcomes were compared between patients treated with TA and those who received conventional therapies. Statistical analyses, including propensity score matching and Cox regression models, were used to account for potential confounders.</p><p><strong>Results: </strong>The TA group demonstrated a significantly longer median overall survival (OS) of 37 months compared to 15 months in the non-TA group (<i>p</i> < 0.001), with five-year OS rates of 32.4% and 9.8%, respectively. Median progression-free survival (PFS) was 36 months in the TA group versus 14 months in the non-TA group, with five-year PFS rates of 24.1% versus 6.3% (<i>p</i> < 0.001). Subgroup analyses showed enhanced survival in patients undergoing targeted therapy and chemotherapy when TA was included. Survival outcomes with TA were comparable to lobectomy, offering a less invasive option for selected patients.</p><p><strong>Conclusions: </strong>Thermal ablation is associated with significant improvements in OS and PFS in patients with advanced NSCLC, providing a viable treatment option for those not eligible for surgery. The results support the integration of TA into standard care protocols, with further prospective studies needed to confirm these findings and optimize treatment strategies.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2449473"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microwave ablation for T1N1M0 papillary thyroid cancer with lymph node oligometastasis (≤3) - a preliminary study with median follow-up beyond 3 years.","authors":"Zhenlong Zhao, Ying Wei, Jie Wu, Shiliang Cao, Na Yu, Yan Li, Wenjia Cai, Ming'an Yu","doi":"10.1080/02656736.2025.2571047","DOIUrl":"https://doi.org/10.1080/02656736.2025.2571047","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the efficacy and safety of microwave ablation (MWA) for T1N1M0 PTC with LN oligometastasis (≤3).</p><p><strong>Materials and methods: </strong>In this retrospective study, 41 patients who underwent MWA for T1N1M0 PTC with LN oligometastasis between June 2018 and June 2023 were included. Progression-free survival (PFS), risk factors for tumor progression and complications were assessed.</p><p><strong>Results: </strong>MWA was successfully performed in all the enrolled patients. The median age was 37 years (IQR: 30.5-46.0), with 13 males and 28 females. After a median follow-up of 43 months (IQR: 37.0-51.5; range: 20-70 months), the 1-, 3-, and 5-year PFS rates were 90.2%, 75.3%, and 62.0%, respectively. The maximum diameter of the PTC was the only significant risk factor for tumor progression (hazard ratio: 7.60; <i>p</i> = 0.010). Major complications included only transient hoarseness, occurring in 7.3% (3/41) of the patients, with full recovery within 2-3 months without treatment.</p><p><strong>Conclusion: </strong>MWA is a feasible treatment option for selected patients with T1N1M0 PTC with LN oligometastasis (≤3), providing favorable therapeutic outcomes and low complication rate.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2571047"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145282478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex parity in stimulation of murine lymphocyte trafficking in response to fever-range systemic thermal therapy.","authors":"Michelle M Appenheimer, Arwen A Tisdale, Daniel T Fisher, Han Yu, Elizabeth A Repasky, Sharon S Evans","doi":"10.1080/02656736.2025.2526118","DOIUrl":"10.1080/02656736.2025.2526118","url":null,"abstract":"<p><p>Murine preclinical studies established that hyperthermia regimens stimulate immunity by mobilizing lymphocyte homing to lymph nodes and tumors. Enhanced lymphocyte trafficking during fever-range systemic thermal therapy (FR-STT) is driven by interleukin-6 (IL-6) upregulation of intercellular adhesion molecule-1 (ICAM-1) on blood vessels in lymph nodes and tumors. However, since hyperthermia regulation of lymphocyte homing was only evaluated in female mice, the response of male mice remains unknown. Here, we investigated the potential sex bias in response to FR-STT by assessing the function of lymph node high endothelial venules (HEV) that are a thermally-responsive vascular site. Although it was feasible to elevate core temperatures to 39.5 ± 0.5 °C for 6 h in female and male mice, males were significantly less tolerant to FR-STT. Under normothermic controls, there was no difference between females and males in baseline intranodal (a) HEV frequency, (b) HEV area, (c) IL-6 concentration, and (d) lymphocyte trafficking. FR-STT further induced similar increases in ICAM-1 expression on HEV and lymphocyte trafficking in lymph nodes in both sexes. While FR-STT did not alter intranodal IL-6 concentrations, findings that IL-6 was higher in lymph nodes than the circulation in both sexes suggest that local IL-6 is responsible for systemic vascular responses to FR-STT. Collectively, these data demonstrate that despite sexual dimorphism in thermal regulation in mice, there was no evidence of a sex bias for lymphocyte homing at checkpoint HEV. Thus, hyperthermia treatment is predicted to be equally effective in boosting immunity in male and female mice when combined with immunotherapy.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2526118"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12345357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of US-guided thermal ablation for elderly patients with solitary papillary thyroid carcinoma: a multicenter preliminary study.","authors":"Na Yu, Ying Wei, Zhenlong Zhao, Shiliang Cao, Jie Wu, Wenjia Cai, Hanxiao Zhao, Ming'an Yu","doi":"10.1080/02656736.2025.2555496","DOIUrl":"https://doi.org/10.1080/02656736.2025.2555496","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the efficacy and safety of US-guided thermal ablation (TA) for solitary papillary thyroid carcinoma (PTC) in elderly patients.</p><p><strong>Materials and methods: </strong>This retrospective study included 91 elderly patients with solitary PTC who were treated with TA. The primary outcome was disease progression. The secondary outcomes included the volume change of ablated tumors, the volume reduction rate (VRR), the rate of complete disappearance, and complications.</p><p><strong>Results: </strong>There were 73 T1a stage, 10 T1b stage and 8 T2 stage PTC patients older than 65 years old included in this study. During a median follow-up of 22.0 months, the overall disease progression rate was 2.2% (2/91). One patient developed a new tumor, and another developed lymph node metastasis (LNM). No patients were diagnosed with local recurrence, lymphatic/distant metastasis, or death due to PTC. At the longest follow-up, 72 months after TA, the median VRR was 100.0%, and 90.9% (10/11) of ablated tumors had been fully absorbed. Transient hoarseness occurred in two patients (2.2%).</p><p><strong>Conclusion: </strong>TA is an effective and safe option for elderly patients with solitary PTC, providing a minimally invasive alternative for those who refuse surgery or active surveillance.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2555496"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-clinical studies investigating the combination of hypofractionated radiation with hyperthermia in a murine tumor and normal skin.","authors":"Charlemagne A Folefac, Priyanshu M Sinha, Niels Bassler, Mateusz K Sitarz, Danny Mortensen, Morten Busk, Haibin Qian, Przemek M Krawczyk, Arlene L Oei, Pernille B Elming, Michael R Horsman","doi":"10.1080/02656736.2025.2545400","DOIUrl":"https://doi.org/10.1080/02656736.2025.2545400","url":null,"abstract":"<p><strong>Introduction: </strong>This preclinical study evaluated the effects of combining hypofractionated radiation (HFRT), either as X-ray photons or protons, with hyperthermia on tumor response and normal tissue damage in mice.</p><p><strong>Methods: </strong>The tumors were C3H mammary carcinomas implanted in the right rear foot of male CDF1 mice, while non-tumor-bearing mice were used to assess normal foot skin. HFRT was delivered in three fractions (5, 10, or 15 Gy) at 3 to 4-day intervals. Hyperthermia (40.5-42.5 °C) was applied once for 60 min, either 30, 90, or 180 min after the final radiation dose. Endpoints included tumor growth delay and moist skin desquamation. Mechanistic studies assessed DNA damage (γ-H2AX foci) 24 h after 3 × 10 Gy, with or without hyperthermia (42.5 °C for 1 h, administered 30 min post-RT), and tumor hypoxia (pimonidazole staining) measured 1 h after the last radiation fraction.</p><p><strong>Results: </strong>Animals responded similarly to X-ray photons and protons in the tumor and skin. Hyperthermia enhanced the response to X-ray photons in both tissues, with temperature and time-interval dependency, showing the greatest effects at higher temperatures and shorter intervals. Protons combined with hyperthermia showed similar results, although with less decay in time-interval effects at 42.5 °C. DNA damage assessments revealed no significant difference between radiation types, but a significant enhancement was seen when tumors were heated at 42.5 °C. Tumor hypoxia was reduced after 3 × 10 Gy irradiation with either radiation type.</p><p><strong>Conclusions: </strong>Combining HFRT with hyperthermia yielded effects comparable to single-dose studies for both tumors and normal tissues. These responses were similar for both X-rays and protons.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2545400"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144986417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mathematical modeling of the effect of stent construction during endoluminal IRE for recanalization of an occluded metal stent.","authors":"Peter Matkulcik, Martin Hemzal, Tomas Rohan, Dalibor Cervinka, Veronika Novotna, Shraga Nahum Goldberg, Tomas Andrasina","doi":"10.1080/02656736.2025.2520362","DOIUrl":"https://doi.org/10.1080/02656736.2025.2520362","url":null,"abstract":"<p><strong>Background: </strong>Intraluminal irreversible electroporation (IRE) can be used for recanalizing occluded metal stents. However, optimal IRE parameters for consistent effects across different stent designs remain unclear. The aim of this study was to simulate the process of stent recanalization <i>in silico</i> by employing finite element analysis.</p><p><strong>Methods: </strong>A virtual model of an occluded biliary stent with an experimental 3-electrode IRE catheter was developed. Electric field distribution, temperature changes, and potential ablation volumes were simulated across various parameters: IRE voltage (300 - 1300 V), stent wire width (0.1 - 0.5 mm) and stent mesh size (0.7 - 5.58 mm). Simulations incorporated five representative stent types commonly used in clinical practice. 685 unique simulations were conducted, analyzing 1162 unique values.</p><p><strong>Results: </strong>Higher voltages generally led to larger ablation zones and increased temperatures. Thinner stent wires and larger mesh sizes also increased the extent of ablation zone. While in-stent ablation was largely independent of stent design, out-of-stent ablation was significantly impacted by mesh size and tissue thickness between the stent and irreversible electroporation electrodes. Voltages above 1000 V produced significant thermal effects, with substantial volumes of tissue heated above 50 °C. Specific stent designs exhibited variations in maximum temperature (72.1 - 83.1 °C) and ablation volume (8.7 - 14.7 mm³).</p><p><strong>Conclusion: </strong>Tailored IRE protocols for different stent designs are required due to differences in in- and out-stent ablation volumes. High voltages (>1000 V) induce both thermal and nonthermal ablation mechanisms.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2520362"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carboprost tromethamine injection enhanced the efficacy of focused ultrasound ablation surgery for hyperintense uterine fibroids: a retrospective study.","authors":"Guangping Wu, Min He, Feng Ran, Li Yunyun, Li Fei, Xiao Zhenghua, Xiaojing Zhang, Zhibiao Wang","doi":"10.1080/02656736.2025.2552814","DOIUrl":"https://doi.org/10.1080/02656736.2025.2552814","url":null,"abstract":"<p><strong>Objective: </strong>To investigate whether carboprost tromethamine injection enhances the efficacy of focused ultrasound ablation surgery (FUAS) for hyperintense uterine fibroids (UFs) on T2-weighted MR imaging (MRI).</p><p><strong>Materials and methods: </strong>In this single-center study, 112 patients with symptomatic UF_S were randomly assigned to either the carboprost trimethylamine injection group (<i>n</i> = 56) or oxytocin group (<i>n</i> = 56) during FUAS ablation conducted between February 1, 2023, and February 28, 2025. Treatment tolerance was assessed using the International Society of Interventional Radiotherapy (SIR) complication grading system. Treatment outcomes and adverse events were compared between groups.</p><p><strong>Results: </strong>In the carboprost tromethamine group, the non-perfused volume (NPV) ratio was 98.38% (IQR: 91.65 - 104.35%), the energy-efficiency factor (EEF) was 2.44 J/mm³ (IQR: 1.38 - 4.83 J/mm³), and the sonication time was 400.00 s (IQR: 205.00 - 605.00 s). However, in the oxytocin group, the NPV ratio was 81.76% (IQR: 59.67 - 89.66%), the EEF was 6.98 J/mm³ (IQR: 3.92 - 14.05 J/mm³), and the sonication time was 733.50 s (295.00 - 1127.50 s). Statistically significant differences in NPV ratio, EEF, and sonication time between the two groups were observed. When FUAS was performed on UFs with 3 - 4 levels of blood flow, there were significant differences between the two groups (<i>p</i> < 0.05). No serious complications were observed during FUAS.</p><p><strong>Conclusion: </strong>Compared with oxytocin, carboprost tromethamine injection significantly reduced the energy for ablating UFS with FUAS, thereby enhancing treatment efficiency. this strategy provides a new option for patients with hyperintense fibroids and grade 3-4 blood flow in fibroids.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2552814"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of thermal ablation in papillary thyroid carcinoma with sonographic tracheal adhesions: a preliminary analysis.","authors":"Xinyi Zhou, Ying Wei, Zhenlong Zhao, Lili Peng, Yan Li, Jie Wu, Shiliang Cao, Na Yu, Ming'an Yu","doi":"10.1080/02656736.2025.2571046","DOIUrl":"https://doi.org/10.1080/02656736.2025.2571046","url":null,"abstract":"<p><strong>Background: </strong>Microwave ablation (MWA) has demonstrated promising efficacy in management of papillary thyroid carcinoma (PTC). Tracheal adhesions present a significant clinical challenge in these patients, necessitating systematic analysis of MWA outcomes to establish evidence-based protocols for this complex subgroup.</p><p><strong>Purpose: </strong>To evaluate safety and efficacy of MWA for PTC with sonographically classified mild and moderate tracheal adhesions.</p><p><strong>Methods: </strong>This retrospective study analyzed 103 pathologically confirmed PTC patients with mild and moderate tracheal adhesions treated by MWA between January 2018 and December 2024. Primary endpoints included technical success and complications; secondary endpoints comprised disease progression, volume reduction rate, and tumor disappearance. Risk factors for hoarseness were screened through logistic analyses and integrated into a predictive nomogram, evaluated using receiver operating characteristic (ROC) curve and calibration chart.</p><p><strong>Results: </strong>Complete ablation was achieved in all patients. Complications were documented in 23.3% of cases, with 20.4% experiencing temporary hoarseness. Disease progression occurred in 1.9% of cases. Complete tumor disappearance was observed in 33.0% of cases, with 90.0% achieving ≥75% volume reduction rate at 2 years follow-up. Multivariable logistic analysis identified minimal tumor-trachea distance ≤3.9 mm (OR = 15.52, 95% CI: 3.93-61.36) and absence of anechoic areas (OR = 4.25, 95% CI: 1.15-15.68) following hydrodissection as significant predictors of hoarseness. The predictive nomogram demonstrated strong discrimination (the area under the ROC curve = .85).</p><p><strong>Conclusions: </strong>Ultrasound-guided MWA demonstrates safety and efficacy for PTC with mild and moderate tracheal adhesions. The developed nomogram may facilitate clinical decision-making during treatment planning.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"42 1","pages":"2571046"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}